Sponsor Deadline
Posted: 4/18/2022

Notice of Intent to Publish a Funding Opportunity Announcement for Acquired Resistance to Therapy Network (ARTNet) (U54 Clinical Trial Not Allowed)

NOTE: This is a Forecasted Opportunity.

The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites applications for Acquired Resistance to Therapy Network(ARTNet). The ARTNet FOA is a reissuance of RFA CA-17-009, which created a Drug Resistance and Sensitivity Network (DRSN) as part of the Cancer Moonshot initiative to accelerate clinical research on drug combinations. While precision oncology approaches are helpful for patient selection based on intrinsic mutations, few strategies exist for acquired resistance including a paucity of research platforms developed from resistant-recurrent tumors. The purpose of the ARTNet is to build upon the DRSN and reprioritize focus on addressing the mechanistic underpinnings of acquired resistance to the full range of treatment modalities (e.g., radiation, chemotherapeutics, targeted agents, immuno-oncology tactics, combined modality treatments).

The FOA will utilize the U54 (Specialized Center-Cooperative Agreements) mechanism. Each ARTNet site shall be structured to test hypotheses that bridge basic experiments, preclinical modeling, and translational research in a synergistic and iterative fashion. It is anticipated that each ARTNet site will respectively have a unique thematic focus guided by an overarching central hypothesis that defines it. Collectively, ARTNet sites will operate as a network with national impact in developing new cancer biology concepts that have potential to inform therapeutic strategies and overcome acquired resistance. ARTNet sites will not support clinical trials. This Notice is being provided to allow potential applicants sufficient time to develop a responsive, multicomponent ARTNet application.


Estimated Post Date: Jul 01, 2021 Estimated Application Due Date: Nov 01, 2021  
Funding Type